Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 7,528 Shares

Key Points

• Tempus AI CFO James William Rogers sold 7,528 shares at an average price of $74.65, totaling approximately $561,965, reducing his position by 5.16% to 138,473 shares.
• The company's quarterly earnings revealed a revenue increase of 89.5% year-over-year, reporting $314.64 million and beating analysts' expectations.
• Overall, Tempus AI has received a consensus rating of "Moderate Buy", with a target price averaging $67.64 set by analysts following recent evaluations.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CFO James William Rogers sold 7,528 shares of the business's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total value of $561,965.20. Following the completion of the transaction, the chief financial officer owned 138,473 shares in the company, valued at $10,337,009.45. This trade represents a 5.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tempus AI Stock Performance

TEM stock traded up $3.43 during trading on Thursday, hitting $76.71. The company had a trading volume of 15,579,085 shares, compared to its average volume of 12,600,730. The firm has a market cap of $13.33 billion, a PE ratio of -64.46 and a beta of 4.98. Tempus AI, Inc. has a 1-year low of $31.36 and a 1-year high of $91.45. The firm has a 50-day moving average price of $63.48 and a 200-day moving average price of $58.98. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The firm had revenue of $314.64 million for the quarter, compared to analysts' expectations of $296.84 million. During the same quarter in the previous year, the firm posted ($6.86) EPS. The firm's revenue for the quarter was up 89.5% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. On average, analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Guggenheim upped their price target on Tempus AI from $65.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, June 30th. Morgan Stanley increased their target price on Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a report on Tuesday, August 12th. Bank of America increased their target price on Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a report on Wednesday, June 25th. Piper Sandler reiterated a "neutral" rating on shares of Tempus AI in a report on Friday, August 8th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $70.00 target price on shares of Tempus AI in a report on Friday, August 8th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Tempus AI has an average rating of "Moderate Buy" and a consensus target price of $67.64.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently made changes to their positions in the business. Concord Wealth Partners grew its position in shares of Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company's stock valued at $26,000 after purchasing an additional 308 shares during the period. Allworth Financial LP grew its position in shares of Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company's stock valued at $29,000 after purchasing an additional 450 shares during the period. Cherry Tree Wealth Management LLC purchased a new stake in shares of Tempus AI in the first quarter valued at $31,000. SouthState Corp grew its position in shares of Tempus AI by 3,761.5% in the second quarter. SouthState Corp now owns 502 shares of the company's stock valued at $32,000 after purchasing an additional 489 shares during the period. Finally, University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Tempus AI in the first quarter valued at $33,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.